Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Trading 03-28 12:17:10 EDT

6.27

-0.16

-2.49%

High6.49	Low6.16	Vol431.25K
Open6.38	D1 Closing6.43	Amplitude5.13%
Mkt Cap459.79M	Tradable Cap427.92M	Total Shares73.33M
T/O2.70M	T/O Rate0.63%	Tradable Shares68.25M
P/B1.90	ROE-68.01%	EPS-1.64
52wk High12.22	52wk Low5.03	P/E-3.82
Dividend0.00	Div.Yield0.00	ROA-30.44%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":6.27,"timestamp":1743178601021,"preClose":6.43,"halted":0,"volume":431250,"delay":0,"floatShares":68249136,"shares":73331690,"eps":-1.643455,"marketStatus":"Trading","change":-0.16,"latestTime":"03-28 12:17:08 EDT","open":6.38,"high":6.49,"low":6.16,"amount":2702840.4,"amplitude":0.051322,"askPrice":6.28,"askSize":507,"bidPrice":6.26,"bidSize":468,"shortable":3,"etf":0,"ttmEps":-1.643455,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":6.43,"preHourTrading":{"tag":"盘前","latestPrice":6.32,"preClose":6.43,"latestTime":"09:20 EDT","volume":1760,"amount":11289.70656,"timestamp":1743168001096},"postHourTrading":{"tag":"盘后","latestPrice":6.4063,"preClose":6.43,"latestTime":"19:54 EDT","volume":23695,"amount":152453.8015,"timestamp":1743119666881},"volumeRatio":0.71407,"impliedVol":0.8693,"impliedVolPercentile":0.464},"requestUrl":"/m/hq/s/MNMD","defaultTab":"news","newsList":[{"id":"2522008197","title":"MindMed Announces New Employee Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2522008197","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522008197?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:01","pubTimestamp":1742846460,"startTime":"0","endTime":"0","summary":"NEW YORK, March 24, 2025----Mind Medicine  Inc.  , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company , with an effective grant date of March 24, 2025. The Options have an exercise price equal to the closing price of MindMed’s common shares on March 21, 2025, the last trading day on which MindMed’s common shares traded prior to the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.The Options were granted as a material inducement to each employee’s employment and were approved by MindMed's Compensation Committee on March 19, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-employee-inducement-grants-200100745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","QID","QLD","MNQmain","USAW.SI","MNMD","TSYW.SI","SQQQ","USJW.SI","PSQ","NVIW.SI","TQQQ","BK4007","NQmain","BK4547"],"gpt_icon":1},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMND","SNPX","BK4539","MYCOF","CMPS","FLHLF","SPRC","NRXP","RVVTF","NUMIF","KTTA","SEEL","SILO","QNTM","BK4139","PBM","ALID","OPTHF","RLMD","MIRA","PHRRF","ATAI","IXHL","BK4547","MDXXF","BK4202","CYBN","AGNPF","BETRF","DRUG","BK4007","ENTBF","MNMD","BK4168","PSYGF","GHRS"],"gpt_icon":0},{"id":"2520093546","title":"MindMed Appoints Matt Wiley as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520093546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520093546?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA63Z4Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2520541217","title":"MindMed Appoints Matt Wiley as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520541217","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520541217?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 17, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer . In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company’s commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet  for generalized anxiety disorder  and major depressive disorder .\"Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,\" said Rob Barrow, Chief Executive Officer of MindMed. \"His proven track record in driving commercial success for novel, first-in-class products like XYREM will be an asset in realizing the significant commercial potential of MM120. As we approach multiple key clinical readouts from our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-matt-wiley-chief-110000560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2357125470.USD","SQQQ","TSYW.SI","NQmain","QID","NVIW.SI","LU2506951792.HKD","LU2294711713.HKD","QLD","PSQ","BK4009","USJW.SI","TQQQ","ODT","MNMD","LU0823414478.USD","BK4547","MNQmain","CCO","BK4007","USAW.SI",".IXIC","LU0823414551.USD","LU2249611893.SGD"],"gpt_icon":1},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KTTA","CMPS","GHRS","SPRC","MDXXF","ATAI","ENTBF","PSYGF","FLHLF","QNTM","IXHL","NRXP","BETRF","ALID","RVVTF","BK4202","SNPX","RLMD","BK4539","AGNPF","CYBN","PBM","MIRA","MNMD","OPTHF","BK4007","MYCOF","SEEL","BK4547","BK4168","BK4139","DRUG","ENVB","PHRRF","NUMIF","SILO","CMND"],"gpt_icon":0},{"id":"2518798399","title":"Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518798399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518798399?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 15:40","pubTimestamp":1741678852,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mind Medicine (MNMD – Research Report), RAPT Thera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mind-medicine-mnmd-rapt-therapeutics-rapt-and-lifemd-lfmd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mind-medicine-mnmd-rapt-therapeutics-rapt-and-lifemd-lfmd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","LFMD","BK4007","MNMD","RAPT","BK4137","BK4139","HCSG","BK4183","BK4167"],"gpt_icon":0},{"id":"2518289954","title":"Mind Medicine’s (MNMD) Recent Achievements Boosting Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2518289954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518289954?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 00:56","pubTimestamp":1741452997,"startTime":"0","endTime":"0","summary":"Mind Medicine ($MNMD) announced its Q4 financials and indicated it is making strides in developing innovative treatments for brain health disorders...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/mind-medicines-mnmd-recent-achievements-boosting-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/mind-medicines-mnmd-recent-achievements-boosting-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4007","BK4547"],"gpt_icon":0},{"id":"2517436191","title":"Mind Medicine Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2517436191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517436191?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:02","pubTimestamp":1741356120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 09:02 ET (14:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517480020","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (MNMD), SurModics (SRDX) and Enhabit, Inc (EHAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480020?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:11","pubTimestamp":1741353062,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mind Medicine (MNMD – Research Report), SurModics (SRDX – Researc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mind-medicine-mnmd-surmodics-srdx-and-enhabit-inc-ehab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mind-medicine-mnmd-surmodics-srdx-and-enhabit-inc-ehab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4547","BK4082","SRDX","HCSG","EHAB","BK4137","BK4007","MNMD"],"gpt_icon":0},{"id":"2517484554","title":"Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484554?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:11","pubTimestamp":1741349460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:11 ET (12:11 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517163295","title":"Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163295?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:32","pubTimestamp":1741271525,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings SummaryMind Medicine (MindMed) Inc MNMD.OQ reported a quarterly adjusted loss of 41 cents per share for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP1HW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517156151","title":"Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156151","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156151?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:03","pubTimestamp":1741262632,"startTime":"0","endTime":"0","summary":"Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.30) by 36.67 percent. This is a 30.51 percent increase over losses of $(0.59) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44162318/mind-medicine-q4-2024-gaap-eps-0-41-misses-0-30-estimate-cash-and-cash-equivalents-of-273-7m-as-of-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517621156","title":"BRIEF-MindMed FY Net Income USD -108.679 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517621156","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517621156?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:00","pubTimestamp":1741262445,"startTime":"0","endTime":"0","summary":"BRIEF-MindMed FY Net Income USD -108.679 Million\n\n\nMar 06 (Reuters) - MindMed FY income from operations USD -103.916 million.\n\nFY basic EPS USD -1.54\nFY operating expenses USD 103.916 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLXB19894:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2517215668","title":"MindMed FY Basic EPS USD -1.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517215668?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLXB19894:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2517156665","title":"MindMed FY Operating Expenses USD 103.916 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156665?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nPLXB19894:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2517215640","title":"MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517215640?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":"--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet  in Generalized Anxiety Disorder ; 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama--. --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder  in 1H of 2025--. --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--. --Company to host a conference call today at 8:00 a.m. EST--. NEW YORK, March 06, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights.Initiated dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-reports-fourth-quarter-full-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","BK4585","ABVC","BK4007","LU0256331488.USD","BK4547","BK4139","ODT","BK4213","APA","BK4588"],"gpt_icon":0},{"id":"2516412620","title":"MindMed to Present at Leerink’s Global Healthcare Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516412620","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516412620?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-present-leerink-global-healthcare-120000193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4547","BK4137","HCSG","MNMD"],"gpt_icon":0},{"id":"2512499254","title":"Press Release: MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512499254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512499254?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 20:03","pubTimestamp":1740052980,"startTime":"0","endTime":"0","summary":"Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2509166242","title":"Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2509166242","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509166242?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 17:12","pubTimestamp":1738833143,"startTime":"0","endTime":"0","summary":"Shares in Mind Medicine ($MNMD) are surging, following a shift in market sentiment regarding possible growth and the potential of a significant app...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/mind-medicine-mnmd-advances-groundbreaking-lsd-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/mind-medicine-mnmd-advances-groundbreaking-lsd-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4007","BK4547"],"gpt_icon":0},{"id":"2509460109","title":"Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509460109","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509460109?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 02:37","pubTimestamp":1738694220,"startTime":"0","endTime":"0","summary":"Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and Human Services Department.The controversial nominee has previously said he believes psychedelic drugs could be useful therapeutics and should be decriminalized.Shares of Mind Medicine, the company better known as MindMed that is working on an LSD-based treatment for anxiety, were up 7.3% at $7.91 on Tuesday. Shares of Compass Pathways, which is developing a psilocybin product for depression, rose 9.9% to $4.74. Shares of ATAI Life Sciences, another developer of psychedelic therapies, surged 21% to $2.25.Kennedy has been a vocal skeptic of vaccines and repeatedly made false claims that they cause autism. He has refused to walk the claim back even at the urging of Sen. Bill Cassidy . Cassidy said he struggled with Kennedy's past comments on vaccines but nonetheless cast the deciding vote in favo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4533","BK4539","NVAX","CMPS","PFE","BK4501","BNTX","BK4535","ATAI","MRNA","BK4139","BK4568","BK4532","BK4007","MNMD","BK4588","BK4585","BK4547","BK4551","BK4534"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":-0.0331},{"period":"1month","weight":-0.0474},{"period":"3month","weight":-0.0599},{"period":"6month","weight":0.0991},{"period":"1year","weight":-0.3232},{"period":"ytd","weight":-0.0761}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.097954},{"month":2,"riseRate":0.75,"avgChangeRate":0.162614},{"month":3,"riseRate":0.25,"avgChangeRate":0.090906},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.020489},{"month":5,"riseRate":0.25,"avgChangeRate":-0.037122},{"month":6,"riseRate":0.5,"avgChangeRate":-0.112493},{"month":7,"riseRate":0.75,"avgChangeRate":0.159384},{"month":8,"riseRate":0.25,"avgChangeRate":-0.108659},{"month":9,"riseRate":0,"avgChangeRate":-0.300494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.039054},{"month":11,"riseRate":0.5,"avgChangeRate":0.060477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.119824}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction